The Patent CliffThin moat
Eli Lilly (LLY) — moat facet
The day protection lapses, copies flood in and the price collapses — the moat with an expiry date.
The patent cliff is the defining hazard of the pharmaceutical business, and it deserves to be understood as a facet of the moat rather than merely a threat to it, because it is inseparable from how patent protection works. Every patented drug approaches a precipice: the date its exclusivity ends, after which generic or biosimilar competitors can enter, and the price and revenue of even the greatest blockbuster fall off a cliff. The monopoly that made the drug so profitable guarantees, by its own expiration, that the profits will one day vanish.
The cliff's severity depends on the drug and its type. For small-molecule pills, generic entry is fast and brutal — prices can collapse ninety percent in a year as multiple copies flood in. For complex biologic drugs, the erosion from biosimilars is typically slower and less complete, because the copies are harder to make and approve, which gives biologics a gentler cliff and a longer tail. Either way, the loss of exclusivity is the single most consequential event in any drug's commercial life.
Managing the cliff is the central strategic task of a drugmaker, and it is why this is a facet worth isolating. A company that lets its patents expire without replacements withers; one that continually refills its portfolio with new patented drugs before the old ones fall thrives. Lilly's fortunes turn on how well it navigates the cliffs ahead — above all the expiration of its incretin blockbusters, whose U.S. compound patent is estimated to run to 2036, with Trulicity's ending in 20271 — and an owner should watch the timing and size of those cliffs, and the pipeline meant to bridge them — a realized-price decline of 13% in the second quarter of 2026 shows the pressure is already real2 — as closely as any single thing about the company.
Holding steady — a permanent feature, not a changing one. Every patented drug faces the same fixed reality: exclusivity ends, copies arrive, revenue falls off a cliff. This facet is that unchanging countdown, neither widening nor narrowing so much as always ticking. Lilly's biologics enjoy a gentler cliff than simple pills, and its incretin cliffs are years off, but the clock runs on every drug. A structural constant of the model that the pipeline exists to outrun.
Volume is outrunning price for now. Price falling faster than volume grows would turn the franchise's growth negative.
Source: Lilly Form 10-Q, quarter ended 30 June 2026 ↗- ReportedLilly's fortunes turn on how well it navigates the cliffs ahead — above all the expiration of its incretin blockbusters, whose U.S. compound patent is estimated to run to 2036, with Trulicity's ending in 2027 — and an owner should watch the timing and size of those cliffs, and the pipeline meant to bridge them — a realized-price decline of 13% in the second quarter of 2026 shows the pressure is already real — as closely as any single thing about the company.Eli Lilly Form 10-K, FY2025 - revenue $65,179M (Mounjaro $22,965M, Zepbound $13,542M, Verzenio $5,723M); gross margin 83.0% (81.3%); R&D $13,337M; marketing, selling and administrative $11,094M; acquired IPR&D $2,910M; net income $20,640M; price -6% and volume +50% (U.S. price -10%, volume +53%); rebates, discounts and returns deducted $62,135M; capital expenditure $7,841M; operating cash flow $16,813M ($8,818M, $4,240M); U.S. compound patents: Cyramza 2026, Trulicity 2027, Jardiance 2029, Verzenio 2031, Olumiant 2032, Mounjaro/Zepbound 2036, Jaypirca 2037, Retevmo 2038, Inluriyo 2039; HHS selected Trulicity and Verzenio in January 2026 for government-set prices effective 2028; six products above $3 billion were 82% of revenue; three wholesalers each 16%-24% of revenue — FY2023-FY2025 · publ. February 2026 · source ↗
- ReportedLilly's fortunes turn on how well it navigates the cliffs ahead — above all the expiration of its incretin blockbusters, whose U.S. compound patent is estimated to run to 2036, with Trulicity's ending in 2027 — and an owner should watch the timing and size of those cliffs, and the pipeline meant to bridge them — a realized-price decline of 13% in the second quarter of 2026 shows the pressure is already real — as closely as any single thing about the company.Eli Lilly Form 10-Q, quarter ended 30 June 2026 - revenue $22,974M (+48%): Mounjaro $9,943M (U.S. $4,791M, outside $5,152M), Zepbound $4,928M, Jardiance $1,232M, Trulicity $1,219M, Verzenio $1,474M; oncology $2,570M, immunology $1,417M, neuroscience $429M; volume +60% and price -13% (U.S. +37%/-3%, outside +113%/-36%); gross margin 85.8% (84.3%); R&D $3,819M; MS&A $3,430M; acquired IPR&D $2,776M; special charges $703M; tax rate 23.3% (16.5%); net income $7,095M; diluted EPS $7.94; H1 capital expenditure $5,259M and operating cash flow $16,023M — Q2 2026 · publ. August 2026 · source ↗